

Investigation Report on China's Recombinant Human Endostatin Market, 2019-2023

<https://marketpublishers.com/r/I30B4DE1749EN.html>

Date: August 2019

Pages: 30

Price: US\$ 2,200.00 (Single User License)

ID: I30B4DE1749EN

Abstracts

DESCRIPTION

In 2008, lung cancer replaced liver cancer to be the malignant tumor with the highest fatality rate in China. Over the past 30 years, lung cancer has become a heavy burden on the Chinese people and society.

In 2017, the number of lung cancer patients in China rose to 800,000; 700,000 people died of lung cancer, accounting for over 20% of the cancer deaths in China. The incidence of lung cancer is growing at an annual rate of more than 20%. It is expected that in 2025, lung cancer will kill nearly 1 million people in China. In 2017, the number of lung cancer patients in China and the number of people died of lung cancer in China both accounted for 40% of the global total. And about 80% of the lung cancer patients had non-small cell lung cancer (NSCLC).

Recombinant Human Endostatin, an angiogenesis inhibitor, was developed by a Chinese enterprise in 1999 and approved by the China Food and Drug Administration (CFDA) in 2005 to be used in the combination chemotherapy for the recurrence and metastasis of NSCLC. Recombinant Human Endostatin acts on vascular endothelial cells to inhibit the movement of endothelial cells that form blood vessels and the formation of tumor angiogenesis and block the nutrition supply to tumor cells. In this way, it inhibits tumor proliferation or metastasis.

The sales value of Recombinant Human Endostatin increased sharply after it was launched in China. It rose from CNY 148 million in 2013 to CNY 272 million in 2017, representing a CAGR of 16.47%.

By Aug. 2019, only one enterprise's Recombinant Human Endostatin has been approved to be sold in China. In the context of worsening environmental pollution and over 300 million smokers, the number of lung cancer patients in China will continue to increase in the next few years. Therefore, the market size of Recombinant Human Endostatin will keep expanding and more enterprises will launch their Recombinant Human Endostatin products in China.

TOPICS COVERED:

Incidence of lung cancer in China

Status of China's Recombinant Human Endostatin market

Prices of Recombinant Human Endostatin in China

Development trends of Recombinant Human Endostatin in China

Contents

1 RELEVANT CONCEPTS OF RECOMBINANT HUMAN ENDOSTATIN

- 1.1 Indications for Recombinant Human Endostatin
- 1.2 Development of Recombinant Human Endostatin in China
- 1.3 Patents and Government Approval on Recombinant Human Endostatin in China

2 SALES OF RECOMBINANT HUMAN ENDOSTATIN IN CHINA, 2013-2017

- 2.1 Sales Value
- 2.2 Sales volume
- 2.3 Sales of Recombinant Human Endostatin by Dosage Form in China, 2013-2017

3 ANALYSIS ON MAJOR MANUFACTURERS OF RECOMBINANT HUMAN ENDOSTATIN IN CHINA, 2013-2017

- 3.1 Analysis on Market Share of Major Manufacturers of Recombinant Human Endostatin
- 3.2 Yantai Medgenn Co., Ltd.

4 PRICES OF RECOMBINANT HUMAN ENDOSTATIN IN CHINA, 2017-2018

- 4.1 Yantai Medgenn Co., Ltd. (Endostar)
- 4.2 Analysis on Potential Competitors

5 PROSPECT OF CHINA'S RECOMBINANT HUMAN ENDOSTATIN MARKET, 2019-2023

- 5.1 Factors Influencing Development of China's Recombinant Human Endostatin Market
 - 5.1.1 Driving Forces and Market Opportunities
 - 5.1.2 Threats and Challenges
- 5.2 Forecast on Market Size
- 5.3 Forecast on Market Trend

Selected Charts

SELECTED CHARTS

Chart Sales of Recombinant Human Endostatin in China, 2013-2017

Chart Sales Value of Recombinant Human Endostatin in Parts of China, 2013-2017

Chart Sales Volume of Recombinant Human Endostatin in China, 2013-2017

Chart Sales Volume of Recombinant Human Endostatin in Parts of China, 2013-2017

Chart Sales Value of Recombinant Human Endostatin Injection in China, 2013-2017

Chart Sales Volume of Recombinant Human Endostatin Injection in China, 2013-2017

Chart Sales Value of Recombinant Human Endostatin by Yantai Medgenn Co., Ltd., 2013-2017

Chart Prices of Recombinant Human Endostatin by Yantai Medgenn Co., Ltd. in Parts of China, 2017-2018

Chart Patents on Recombinant Human Endostatin in China

Chart Government Approval on Recombinant Human Endostatin in China

Chart Forecast on Sales Value of Recombinant Human Endostatin in China, 2019-2023

I would like to order

Product name: Investigation Report on China's Recombinant Human Endostatin Market, 2019-2023

Product link: <https://marketpublishers.com/r/I30B4DE1749EN.html>

Price: US\$ 2,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I30B4DE1749EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970